Global Demand for Antinuclear Antibody Test market was valued at approximately USD 951.2 million in 2019, and is expected to generate revenue of around USD 2038.2 million by end of 2026, growing at a CAGR of around 11.5 % between 2020 and 2026.
According to the report, global demand for Antinuclear Antibody Test market was valued at approximately USD 951.2 million in 2019, and is expected to generate revenue of around USD 2038.2 million by end of 2026, growing at a CAGR of around 11.5 % between 2020 and 2026.
Global Antinuclear Antibody Test Market: Overview
The antinuclear antibodies are autoantibodies that attach to the specific contents of the nucleus present in the cell. They are also known as antinuclear factor or ANF. The autoantibodies are produced in the human body against the foreign particles but in some cases, the antibodies are produced against human antigen itself. Thus, antinuclear antibody test helps detect the autoantibodies present in the human blood serum. The most commonly used ANA tests include indirect immunofluorescence and enzyme-linked immunosorbent assay test. After the detection of these antinuclear antibodies, its various subtypes can also be determined.
Global Antinuclear Antibody Test Market: Growth Factors
The major factors responsible for the growth of the global antinuclear antibody test market are growing number of autoimmune diseases and also the escalating number of reagent rental agreements. The growing population results in the rise of various diseases in a number of regions which in turn increases the demand for antinuclear antibody test products and fuels the global market growth. The antinuclear antibody test’s accuracy and immediate results render its vast use in the medical field and thus help drive the growth of the global market. But, the cost of these tests makes it a little unaffordable for the customers, which in turn hamper its sale in the global market.
Global Antinuclear Antibody Test Market: Segmentation
The global antinuclear antibody test market is bifurcated on the basis of disease, product, end user, technique, and region. The disease segment is further categorized into rheumatoid arthritis, systemic lupus erythematosus, scleroderma, Sjögren’s Syndrome, and other diseases. The product segment is divided into systems, software and services, and reagents & assay kits. The end user segment is bifurcated into physician office laboratories, hospitals, clinical laboratories, and other end users. The technique segment is classified into the multiplex assay, ELISA, and immunofluorescence assay. The assay kits and reagents and hospitals segment are expected to dominate the global market and also helps in increasing the global market growth rate.
Global Antinuclear Antibody Test Market: Regional Analysis
North America is expected to lead the global antinuclear antibody test market followed by Europe, Asia, and the Rest of the World. The major reason for the North American market growth is primarily due to the high incidence of autoimmune diseases, healthcare spending, growing population, and rising number of individuals having medical insurance in the U.S.
Global Antinuclear Antibody Test Market: Competitive Players
The key players in the antinuclear antibody test market include ERBA Diagnostics, Inc., Alere Inc., Trinity Biotech plc, Bio-Rad Laboratories, Inc., Thermo Fisher Scientific, Inc., and Antibodies, Inc. The other players in the global market include Immuno Concepts, EUROIMMUN AG, Zeus Scientific, Inc, and Inova Diagnostics. These major companies adopt a number of strategies such as agreements, contracts, new test launch, joint ventures, mergers, and acquisitions in order to obtain a standard position in the market.
Global Antinuclear Antibody Test Market: Regional Segment Analysis
What Report Provides